Microbot Medical (Microbot Medical) ROCE % : -177.83% (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Microbot Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Microbot Medical's annualized ROCE % for the quarter that ended in Mar. 2024 was -177.83%.

Microbot Medical ROCE % Historical Data

The historical data trend for Microbot Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical ROCE % Chart

Microbot Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-42.49

-31.76

-57.19

-120.78

-168.81

Microbot Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-187.67	-127.91	-120.02	-157.41	-177.83

Microbot Medical ROCE % Calculation

Microbot Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-10.136	/	( ( (9.537 - 2.069)	+	(8.327 - 3.786) )	/ 2 )
	=	-10.136	/	( (7.468	+	4.541)	/ 2 )
	=	-10.136	/	6.0045
	=	-168.81 %

Microbot Medical's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-9.536	/	( ( (8.327 - 3.786)	+	(7.367 - 1.183) )	/ 2 )
	=	-9.536	/	( ( 4.541	+	6.184 )	/ 2 )
	=	-9.536	/	5.3625
	=	-177.83 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Microbot Medical (NAS:MBOT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Microbot Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Microbot Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbot Medical (Microbot Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (NAS:MBOT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CY9D:Germany

Address

25 Recreation Park Drive, Unit 108, Hingham, MA, USA, 02043

Website

https://microbotmedical.com

Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.

Executives

Rachel Vaknin	officer: Chief Financial Officer	DROR 3/10, ZICHRON YAAKOV L3 3090216
Simon Sharon	officer: General Manager & CTO	8 HAMADA STREET, ZICHRON YAACOV L3 3090708
Yoseph Bornstein	director, 10 percent owner	16 IRUS STREET, ROSH HA'AYIN L3 4858022
Tal Baruch Wenderow	director	1149, BEACON STREET, NEWTON MA 02461
Eyal Morag	officer: Chief Medical Officer	BONEY HAEAR 3 STREET, APT #13, TEL AVIV L3 6937303
Aileen Ptucha Stockburger	director	26 WELLINGTON CT, BELLE MEADE NJ 08502
Harel Gadot	director, 10 percent owner, officer: Chairman and CEO	5 VILLAGE LANE, HINGHAM MA 02043
Joseph Mona	10 percent owner	808 HAMPTON ST, COLUMBIA SC 29201
Prattipati Laxminarain	director	3 HEWINS FARM ROAD, WELLESLEY MA 02481
Yoav Zvi Waizer	director	8 HAVERED STREET, RAANANA L3 4352308
Moshe Shoham	director	22 BEDOLACH STREET, HOSHAYA L3 1791500
Leon Lewkowicz	10 percent owner	GORDON STREET 10, APARTMENT 7, TEL-AVIV L3 63458
Martin J. Madden	director	C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Yehezkel Himelfarb	officer: General Manager & COO	32 BEN YOSEF STREET, TEL-AVIV L3 6912530
Sandra Berkson	10 percent owner	C/O SABER HOLDING GMBH, WEIN KRUMMBAUMGASSE C4 1020